Celularity (CELUW) Long-Term Deferred Tax (2019 - 2025)
Celularity (CELUW) reported Long-Term Deferred Tax of $192.6 million for Q4 2025, up 6.15% year-over-year from $181.4 million in Q4 2024, and up 6.15% quarter-over-quarter from $181.4 million in Q4 2024.
Celularity (CELUW) Long-Term Deferred Tax (2019 - 2025) Analysis & Trends
Celularity (CELUW) has 3 years of Long-Term Deferred Tax data on file, last reported at $192.6 million in Q4 2025.
- Long-Term Deferred Tax for Q4 2025 came in at $192.6 million, up 6.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $192.6 million (up 6.15% YoY), and the FY2025 annual result was $192.6 million, up 6.15% from the prior year.
- Long-Term Deferred Tax climbed to $192.6 million in Q4 2025 per CELUW's latest filing, from $181.4 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $192.6 million in Q4 2025 and troughed at $181.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Celularity | - | - | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 192.58 Mn |
| Dec 31, 2024 | 181.42 Mn |
| Dec 31, 2019 | 1,653.00 |